Guangdong Zhongsheng Pharmaceutical Co., Ltd.

XSEC:002317 Stock Report

Market Cap: CN¥10.2b

Guangdong Zhongsheng Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

Guangdong Zhongsheng Pharmaceutical has been growing earnings at an average annual rate of 10.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 3.9% per year. Guangdong Zhongsheng Pharmaceutical's return on equity is 2.3%, and it has net margins of 5.4%.

Key information

10.3%

Earnings growth rate

9.9%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate3.9%
Return on equity2.3%
Net Margin5.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Guangdong Zhongsheng Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:002317 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,447133993132
30 Jun 242,493142973131
31 Mar 242,5051751,010131
31 Dec 232,6112631,044127
30 Sep 232,7563531,127149
30 Jun 232,8333281,205152
31 Mar 232,7473871,192157
01 Jan 232,6763221,173157
30 Sep 222,5972131,173138
30 Jun 222,5451921,110153
31 Mar 222,4892951,103139
01 Jan 222,4292781,086137
30 Sep 212,409-4141,083143
30 Jun 212,321-3301,084120
31 Mar 212,122-423967116
31 Dec 201,896-427852114
30 Sep 201,923251833135
30 Jun 202,010207879134
31 Mar 202,307244940139
31 Dec 192,532318978133
30 Sep 192,53845496789
30 Jun 192,47446490288
31 Mar 192,37843985785
31 Dec 182,36243686684
30 Sep 182,30645582273
30 Jun 182,19744772398
31 Mar 182,12543269182
31 Dec 171,96442066768
30 Sep 171,85542763445
30 Jun 171,8374397190
31 Mar 171,7134327240
31 Dec 161,6924147300
30 Sep 161,6733807290
30 Jun 161,6403716840
31 Mar 161,6683256920
31 Dec 151,5782976650
30 Sep 151,4942766260
30 Jun 151,4332576090
31 Mar 151,3672385890
31 Dec 141,3092255570
30 Sep 141,2342195180
30 Jun 141,1902114850
31 Mar 141,1171944570
31 Dec 131,0901884450

Quality Earnings: 002317 has high quality earnings.

Growing Profit Margin: 002317's current net profit margins (5.4%) are lower than last year (12.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 002317's earnings have grown by 10.3% per year over the past 5 years.

Accelerating Growth: 002317's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002317 had negative earnings growth (-62.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).

Return on Equity

High ROE: 002317's Return on Equity (2.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 15:02
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guangdong Zhongsheng Pharmaceutical Co., Ltd. is covered by 15 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhi Xue DiaoAvic Securities Co., Ltd
Shanshan LiChina Merchants Securities Co. Ltd.
Sophia ZhangChina Stock Investment Research Co. Ltd. (GZ500..com)